Contributions
Abstract: PB1834
Type: Publication Only
Session title: Transfusion medicine
Background
Supportive treatments have vital importance in pediatric oncology patients, besides the treatment intended to cancer.
Aims
We aimed to define the frequency and thresholds of erythrocyte and platelet transfusions which are administered to pediatric hematology and oncology patients and to investigate the effects of transfusions on outcome.
Methods
Eighty leukemia (31.6%) and 173 lymphoma or solid tumor (68.4%) patients who were diagnosed and treated in Dokuz Eylül University Pediatric Hematology and Oncology Departments between the January 1, 2013 and January 1, 2018 and transfused with erythrocyte and/or platelet suspension at least for one time period in the course of their treatments are involved in this study. The data of the patients were scanned by clinical follow-up records and DEU Hospital Blood Bank records, retrospectively.
Results
A total of 1389 units of erythrocyte suspension (ES) and 1357 units of platelet suspension (PS) were administered to the leukemia group; 1604 units of erythrocyte suspension and 1243 units of platelet suspension were administered to the lymphoma and solid tumor group. A significant difference was detected between the leukemia and solid tumor groups in terms of ES and PS transfusion numbers; as the leukemia group had more transfusions (p<0.001). Pretransfusion mean hemoglobin and platelet values were 7.3±0.69 (6.2-11.7) g/dL and 22.8±6.95 (10.5-53.3)x109/L in leukemia patients and 8.2±1.21 (5-13.9) g/dL and 30±30.86 (4.3-260) x109/L in lymphoma and solid tumor patients, respectively. A positive correlation was detected between platelet values at initial diagnosis and total number of PS transfusion numbers of leukemia patients (p<0.001). There was no relation between Hb value at diagnosis and ES transfusion numbers. In lymphoma or solid tumor patients; negative correlation was found between Hb levels at diagnosis and ES transfusion numbers (p=0.005). When the patients were compared in terms of survival rates as classified according to pretransfusion mean Hb and platelet values, the overall survival rate was found to be shorter in leukemia patients whose pretransfusion mean hemoglobin and platelet values were above 7.5 gr/dL and 30 x109/L, respectively (Log rank p=0.044 and 0.046). Event free survival rates were also negatively affected in leukemia patients whose pretransfusion hemoglobin was above 7.5 gr/dL (Log rank p=0.006). There was no significant association between pretransfusion values and survival rates in patients with lymphoma and solid tumors.
Conclusion
Total ES and PS transfusion numbers were higher in patients with leukemia in comparison with patients with lymphoma and solid tumors. On the other hand, pretransfusion Hb and platelet thresholds were found to be higher in the lymphoma and solid tumor patients in comparison with the leukemia group. Leukemia patients with higher pretransfusion Hb and platelet thresholds were found to have lower survival rates; however, studies including more homogeneous and extensive patient groups are needed to demonstrate this association more clearly.
Keyword(s): Leukemia, Outcome, Solid tumor, Transfusion
Abstract: PB1834
Type: Publication Only
Session title: Transfusion medicine
Background
Supportive treatments have vital importance in pediatric oncology patients, besides the treatment intended to cancer.
Aims
We aimed to define the frequency and thresholds of erythrocyte and platelet transfusions which are administered to pediatric hematology and oncology patients and to investigate the effects of transfusions on outcome.
Methods
Eighty leukemia (31.6%) and 173 lymphoma or solid tumor (68.4%) patients who were diagnosed and treated in Dokuz Eylül University Pediatric Hematology and Oncology Departments between the January 1, 2013 and January 1, 2018 and transfused with erythrocyte and/or platelet suspension at least for one time period in the course of their treatments are involved in this study. The data of the patients were scanned by clinical follow-up records and DEU Hospital Blood Bank records, retrospectively.
Results
A total of 1389 units of erythrocyte suspension (ES) and 1357 units of platelet suspension (PS) were administered to the leukemia group; 1604 units of erythrocyte suspension and 1243 units of platelet suspension were administered to the lymphoma and solid tumor group. A significant difference was detected between the leukemia and solid tumor groups in terms of ES and PS transfusion numbers; as the leukemia group had more transfusions (p<0.001). Pretransfusion mean hemoglobin and platelet values were 7.3±0.69 (6.2-11.7) g/dL and 22.8±6.95 (10.5-53.3)x109/L in leukemia patients and 8.2±1.21 (5-13.9) g/dL and 30±30.86 (4.3-260) x109/L in lymphoma and solid tumor patients, respectively. A positive correlation was detected between platelet values at initial diagnosis and total number of PS transfusion numbers of leukemia patients (p<0.001). There was no relation between Hb value at diagnosis and ES transfusion numbers. In lymphoma or solid tumor patients; negative correlation was found between Hb levels at diagnosis and ES transfusion numbers (p=0.005). When the patients were compared in terms of survival rates as classified according to pretransfusion mean Hb and platelet values, the overall survival rate was found to be shorter in leukemia patients whose pretransfusion mean hemoglobin and platelet values were above 7.5 gr/dL and 30 x109/L, respectively (Log rank p=0.044 and 0.046). Event free survival rates were also negatively affected in leukemia patients whose pretransfusion hemoglobin was above 7.5 gr/dL (Log rank p=0.006). There was no significant association between pretransfusion values and survival rates in patients with lymphoma and solid tumors.
Conclusion
Total ES and PS transfusion numbers were higher in patients with leukemia in comparison with patients with lymphoma and solid tumors. On the other hand, pretransfusion Hb and platelet thresholds were found to be higher in the lymphoma and solid tumor patients in comparison with the leukemia group. Leukemia patients with higher pretransfusion Hb and platelet thresholds were found to have lower survival rates; however, studies including more homogeneous and extensive patient groups are needed to demonstrate this association more clearly.
Keyword(s): Leukemia, Outcome, Solid tumor, Transfusion